RxDoctor Payments Data

Sonia Khatter, MD

Rheumatology · Denver, CONPI 1174056592

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,912 of the $2,736 with a category attached, or 69.9%. 10 manufacturers reported payments, led by AstraZeneca at 47.6% of the total.

$2,736in general payments, 2019–2025

Across 32 payments — averaging $85.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amgen$735
  • Lilly USA, LLC$189
  • UCB, Inc.$183
  • Johnson & Johnson$99
  • Kyowa Kirin, Inc.$98
  • plus $130 from 4 others

What the payments were for

  • Consulting fees$72527%
  • Food & beverage$1,91270%
  • Education$994%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,736 in reported general payments places this provider in the 60th percentile of 108 rheumatology providers in Colorado.

See all rheumatology providers in Colorado

Medicare billing

Part B allowed, 2024
$545,630
Medicare patients
238
Services billed
36,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept51$380,228
Orencia ClickjectAbatacept53$343,684
Humira(Cf) PenAdalimumab28$241,444
ForteoTeriparatide37$172,452
XeljanzTofacitinib Citrate18$118,649
RinvoqUpadacitinib14$116,900
Cosentyx Sensoready (2 Pens)Secukinumab16$116,106
EnbrelEtanercept11$79,835
KevzaraSarilumab20$75,698
Actemra ActpenTocilizumab19$58,181
TymlosAbaloparatide15$44,603
Teriparatide15$32,852
MethotrexateMethotrexate Sodium250$5,671
Hydroxychloroquine Sulfate138$5,211
Diclofenac Sodium19$1,660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCForteo$189$172,45237 claims
AbbVieRinvoq$85$116,90014 claims
AmgenEnbrel$735$79,83511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 108 rheumatology providers in Colorado.

Other rheumatology in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →